glp-1 drugs key developments 2025 trends 2025: real-world data, patient outcomes & future therapies GLP-1 Weight Loss Drug Enforcement

Koehler JA, Baggio LL, Yusta B, Longuet C, Rowland KJ, Cao X, et al

377 , 839848 (2017) J.F.E

The groups were further subdivided based on whether they were taking semaglutide or a non-GLP-1 RA medication

Clinical Trial Results: Tirzepatide (All Forms Mounjaro, Zepbound, Compounded): Because the active ingredient is identical, effectiveness is the same: SURMOUNT-1 Trial Results (72 weeks): 15 mg dose: 22.5% average body weight loss 10 mg dose: 21.4% average body weight loss 5 mg dose: 15.0% average body weight loss 96% of patients lost at least 5% of body weight 89% of patients lost at least 10% of body weight 63% of patients lost at least 20% of body weight Real-World Effectiveness: Compounded tirzepatide produces identical results to brand-name because its the same molecule at the same doses

K., Cox, L

Crazy, right